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Summary
The cloning of the CFTR gene has made it technically
possible to avert the unwanted birth of a child with cystic
fibrosis (CF). Several large trials offering prenatal CF
carrier screening suggest that such screening is practical
and that identified carriers generally use the information
obtained. Therefore, a critical question is whether the
cost of such screening is justified. Decision analysis was
performed that used information about choices that
pregnant women were observed to make at each stage
in the Rochester prenatal carrier-screening trial. The cost
of screening per CF birth voluntarily averted was esti-
mated to be $1,320,000–$1,400,000. However, the life-
time medical cost of the care of a CF child in today’s
dollars was estimated to be slightly 1$1,000,000. There-
fore, despite both the high cost of carrier testing and the
relative infrequency of CF conceptions in the general
population, the averted medical-care cost resulting from
choices freely made are estimated to offset ∼74%–78%
of the costs of a screening program. At present, if it is
assumed that a pregnancy terminated because of CF is
replaced, the marginal cost for prenatal CF carrier
screening is estimated to be $8,290 per quality-adjusted
life-year. This value compares favorably with that of
many accepted medical services. The cost of prenatal CF
carrier screening could fall to equal the averted costs of
CF patient care if the cost of carrier testing were to fall
to $100.
Introduction
Cystic fibrosis (CF) (MIM 219700) is the most common
serious genetic disease in Caucasians (Welsh et al. 1995).
Treatment, although improving, remains burdensome
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and expensive. Until markedly improved treatment is
available, prevention deserves consideration. Prevention
involves offering population carrier screening before or
early in pregnancy, prenatal diagnosis of carrier couples,
and selective pregnancy termination. The cloning of the
CFTR gene (Riordan et al. 1989; Rommens et al. 1989)
has made population carrier screening possible. Several
features of CF screening have raised serious concerns,
including the very large number of potential testees, the
imperfect sensitivity of the test, and the significant cost
of the test.
Since genetic screening is expensive, there is increasing
pressure to weigh the benefits of screening programs
against their costs. Economic evaluations have been per-
formed for a number of types of genetic screening—for
example, carrier screening for Tay-Sachs (Nelson et al.
1978) and for beta-thalassemia (Attanasio et al. 1980;
Ostrowsky et al. 1985; Old et al. 1986; Modell and
Kuliev 1991), prenatal screening for Down syndrome
(Hagard and Carter 1976; Sadovnick and Baird 1981;
Gill et al. 1986) and for neural tube defects (Chamber-
lain 1978; Henderson 1982; Modell and Kuliev 1993),
and newborn screening for phenylketonuria (Barden et
al. 1984).
When the U. S. Congress Office of Technology As-
sessment (1992) analyzed CF carrier screening, it found
a paucity of experience-based data on the general
public’s attitudes toward key factors such as willingness
to undergo CF carrier screening and to terminate CF
affected pregnancies. We recently have reviewed pub-
lished trials of prenatal CF carrier screening (Rowley et
al. 1997). A trial that we have conducted in Rochester,
NY (Loader et al. 1996), assessed what proportion of
pregnant women are likely to be offered screening and
what proportion are likely to accept the test if it is of-
fered free by their own physician. Women found to be
carriers generally followed through with partner testing
and, if they were found to be at risk, with prenatal di-
agnosis. Women who would not consider pregnancy ter-
mination for CF generally declined screening.
In this article, we use data from the Rochester trial
for an economic evaluation of population carrier screen-
ing. We present data intended to answer the following
questions: (1) what is the cost per CF birth voluntarily
averted? (cost-effective analysis), (2) to what extent is
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this cost balanced by costs of medical care averted? (cost-
benefit analysis), (3) how is the evaluation altered by
consideration of the effect that CF has on the quality of
life of the child and parent? (cost-utility analysis), and
finally, how are future technological changes apt to affect
CF carrier screening cost-effectiveness?
This analysis does not argue for or against population
carrier screening for CF. In particular, it is not intended
to imply that such screening should be adopted only if
it saves money; rather, the purpose of our analysis is to
inform the policy-making process, a process that must
take into account a variety of medical, social, and ethical
perspectives.
Methods
Design of Trial
Elsewhere we have described the design and prelim-
inary results of this study, with regard to participation
by both providers (Rowley et al. 1993) and patients
(Loader et al. 1996; Levenkron et al. 1997). In brief, we
enlisted providers by presenting a description of the trial
to the obstetrical staffs of the five hospitals in Monroe
County that have delivery services. We offered both free
testing to all their female patients who were of repro-
ductive age, x18 years old, and free counseling of all
carriers, with the understanding that providers would
offer screening to all such patients, pregnant or not.
Subsequently, our genetic counselor made a personal
visit to each practice expressing an interest in partici-
pating, to explain the project to the office staff and to
leave brochures (reproduced in Loader et al. 1996), as
well as consent/decline forms, to assist the practice in
the pretest education of patients.
If a patient was found to be a carrier, she was notified
by telephone and was invited to receive an explanation
by the project’s genetic counselor. On arrival for coun-
seling, the carrier was invited to participate in an eval-
uation of CF carrier screening involving both the com-
pletion of several questionnaires and follow-up. At the
time of counseling, the manifestations, inheritance, and
treatment of CF, as well as the patient’s options, were
presented; the patient’s questions were answered; and
the patient was offered carrier testing of the fetus’s father
(hereafter called “partner”).
If the partner was tested and found to be negative,
the patient was informed that the residual probability
of having a child with CF in any given pregnancy was
∼1/666. If the partner tested positive, the couple was
invited for a more detailed description of the clinical
manifestations and management of CF and was offered
prenatal diagnosis. Of the 4,879women tested, 124were
found to be CF carriers. Of these 124, 106 partners
(85%) were tested. In 5 of these 106 couples, the partner
also was shown to be a carrier, and prenatal diagnosis
was chosen by 4 of these 5 couples. At least three of the
four couples having prenatal diagnosis said that they
would terminate if the fetus were affected (the fourth
couple was not resolute), although none of the fetuses
proved to be affected. Ninety percent of the 4,879
women tested were pregnant; providers did not find the
offering of testing to nonpregnant women to be an ur-
gent matter. Among pregnant women, the acceptance
rate was 57%.
Methods of Economic Analysis
For this analysis, we adopted the perspective of so-
ciety; that is, we attempted to include all significant
costs, regardless of the identity of the payer. The family
was chosen as the unit of analysis, in order to consider
the impact on the quality of life and earnings of parents
having a CF child and the effect that the risk had on
their reproductive plans. For each couple, the calcula-
tions consider only a single pregnancy, unless the couple
terminates a pregnancy because of CF; in such a case, a
replacement pregnancy also is considered.
The economic appraisal was included prospectively as
part of a clinical trial, as suggested by Drummond and
Davies (1991). Our CF carrier screening trial differed
from many others in one regard that significantly affects
costs. Many trials have been conducted, predominantly
in teaching hospitals, and, in some cases, the offer of
screening has been made by research staff. To identify
outcomes likely to occur should CF carrier screening
become widespread, our trial was region wide, utilized
all providers willing to participate, and involved the offer
of screening by patients’ own physicians or the physi-
cians’ staffs. The economic result is a saving of the cost
of pretest education by a genetic professional, although,
as has been noted elsewhere (Loader et al. 1996), a cost
was incurred in terms of imperfect understanding of the
fact that a negative test result does not guarantee that
one cannot have a child with CF.
Most of the probabilities used in this analysis reflect
the data collected in our trial. Two exceptions should
be noted here. First, although five pregnancies under-
went prenatal diagnosis, one pregnancy was lost shortly
thereafter, presumably as a result of the procedure. This
20% loss rate from amniocentesis is not used in the
calculation, because the loss rate in large series is only
∼0.3% (National Institute of Coronary Heart Disease
National Registry for Amniocentesis Study Group 1976)
and, therefore, has not been included in our calculations.
Second, none of the six pregnancies at risk involved a
homozygously affected offspring. Yet, one can be con-
fident that, in a large series, close to 25% of the fetuses
will have CF; and therefore a value of 25% is used in
the analysis.
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In contrast to the probabilities, the cost estimates, in
many cases, are derived from national samples. We did
not use our actual cost of laboratory testing, because
the latter was performed under contract, at less than the
current commercial price. We also did not use Rochester
figures for the cost of care of a CF child, because Roch-
ester traditionally has had health-care costs below the
national average. The software package used was
SMLTREE (Hollenberg 1988).
Assumptions
It is generally agreed that individuals who are close
adult relatives of either persons with CF or known CF
carriers and who are planning to have children should
be offered carrier testing (“Genetic Testing for Cystic
Fibrosis” statement of the National Institutes of Health
[1997]). Of the 4,879 women screened in our study, only
7 indicated that they or their partner had such a family
history. Therefore this analysis assumes that no one of-
fered testing had such a family history.
We have assumed that women are tested only when
pregnant. In the trial that we conducted, even though
we urged obstetrician-gynecologists to offer screening to
all their patients, pregnant or not, and although testing
and carrier counseling were offered free, 90% of the
women who actually were offered screening were preg-
nant. Therefore, on these grounds and others, we are
confident that, in a nonresearch setting, those who
are offered screening will be predominantly pregnant
women.
We also have assumed that screening will be offered
in time for the consideration of prenatal diagnosis,
should the couple be found to be at risk. If the sample
tested is blood, as was the case for most of our patients,
the sample is conveniently collectedwhen blood is drawn
for other purposes, during the first prenatal visit. In our
study, only 1 of the 109 pregnant women who were
identified as being carriers was too late in gestation for
consideration of prenatal diagnosis. In a population in
which the first prenatal visit often is late in gestation,
this constraint would have to be considered. We further
assumed that, if screening was declined or if the result
was negative, the pregnancy was carried to term. Even
though some pregnancies are lost after prenatal care is
initiated, a maternal-carrier diagnosis made in that preg-
nancy will inform a subsequent pregnancy.
We have not taken into account the small risk of a
false-positive result in carrier testing. The false-negative
rate is considered under the heading of test sensitivity.
We assumed that fetal diagnosis was 100% accurate,
since it was offered only if both parents had a detectable
mutation. We have not considered misidentification or
unavailability of the fathers of the fetuses. In each preg-
nancy of carrier women in our study, the father allegedly
was identifiable and locatable, although this may not be
the case in other locales.
We have assumed that women found to be carriers
are offered fetal testing only if the father of the fetus
also is found to be a carrier. In our study, 0 of the 101
couples in which the woman was a carrier but in which
the partner was negative requested fetal testing; all
seemed reassured that their risk of having a CF child
(∼1/666) was acceptably low.
To estimate treatment benefits, we used a methodol-
ogy known as “quality-adjusted life-expectancy analy-
sis.” In this method, published life expectancy is adjusted
by health-related quality of life. For example, in tradi-
tional life-expectancy analysis, an individual is scored
1.0 for each remaining year of life and is scored 0.0 if
dead. In quality-adjusted life-expectancy analysis, well-
ness scores of 0.0–1.0 are assigned on the basis of health-
related quality of life.
To estimate the level of wellness on the 0.0–1.0 con-
tinuum, we used the time–trade-off method. In this
method, the subject is offered a choice of living either
for a defined period of time in perfect health or for a
variable amount of time in an alternative state that is
less desirable. Presumably, all subjects would choose a
year of wellness versus a year with some health problem.
However, by reducing the time of wellness and leaving
the time in the suboptimal health state fixed (such as 1
year), an indifference point can be determined. For ex-
ample, a subject may rate being in a wheelchair for 1
year as equivalent to perfect wellness for year. The12
time–trade-off method is appealing theoretically because
it generates results conceptually equivalent to a quality-
adjusted life year (QALY). The health-related quality of
life was assessed, for teenage children, by asking them
the question; in the case of younger children, their par-
ents were asked the question and to adopt the child’s
point of view. In addition, all parents were asked not
about their own health but about the effect of having a
child with CF on their own quality of life. All families
with CF children cared for in the Cystic Fibrosis Clinic
of the University of Rochester Medical Center were in-
vited to participate. Those participating represented the
full range of severity of the disease.
These analyses assumed that the parents were each 25
years of age when the pregnancy occurred. Expected age
at death was assumed to be 78.8 years for mothers, 71.9
years for fathers, 73 years for unaffected children, and
30 years for affected children (Cystic Fibrosis Founda-
tion, personal communication). Costs were estimated in
terms of 1996 dollars.
Results
For our analysis we created a base model using the
most probable assumption and conducted sensitivity
analyses using a range of values for most variables.
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Table 1
Cost Values Used for Base Case and Sensitivity Analysis
Variable
Base
Value Sensitivity Range Source(s)
Direct-care costs per CF child per year $43,083 $10,000–$60,000 Cystic Fibrosis Foundation
Amount of time spent on indirect care per year 938 h 700–1,000 h U.S. Congress Office of Technology Assessment (1992)
Indirect-care cost per hour $10 (Not varied) U.S. Congress Office of Technology Assessment (1992)
Cost of offering screeninga $20 $20–$100 U.S. Congress Office of Technology Assessment
(1992), present study
Cost of laboratory test $150 $20–$200 Genzyme
Cost of counseling carriers $150 $100–$200 Market survey
Cost of couple counseling $60 (Not varied) Present study
Cost of prenatal diagnosis $900b (Not varied) Present study
Cost of termination $900 $400–$1,200 U.S. Congress Office of Technology Assessment (1992)
Cost of normal delivery $3,700 $1,800–$5,000 Present study
Discount rate 3% 0%–7%
a Includes professional time, clerical time, cost of brochure, and cost of consent form.
b Includes cost of amniocentesis ($315) and cost of DNA analysis ($585).
Estimate of Costs
Cost estimates for the base case and sensitivity anal-
yses are presented in table 1. Noteworthy is the recent
rapid increase in annual direct medical cost of care for
CF—from ∼$10,000 in 1990 (U.S. Congress Office of
Technology Assessment 1992) to 1$43,000 today (Cys-
tic Fibrosis Foundation, personal communication)—as a
result of therapeutic advances such as lung transplan-
tation and mucolytic therapy. CF is distinguished also
by a large investment in caregiver time, estimated to
average 938 h/year (U.S. Congress Office of Technology
Assessment 1992). At $10/h, this amounts to $9,380.
The base cost of the carrier test is assumed to be $150
(Genzyme, personal communication). In the calculation
of the cost of screening, research-related activities that
would not be required in a service setting were not
included.
Probabilities
The probabilities used are summarized in table 2. We
found that among pregnant women the acceptance rate
for screening was 57%. Others have observed higher
rates, and a rate as high as 100% is considered in the
sensitivity analysis. The test sensitivity assumed for the
base case analysis was 85%, for our largely Caucasian
acceptor group, although Genzyme claims 90% sensi-
tivity for persons of northern European descent for its
current 70-mutation test (Klinger 1997).
Most of the women whom we identified as being car-
riers either had the father of the fetus tested or had a
specific reason for not doing so (Loader et al. 1996).
The 85% rate of partner testing is derived from our
study (for 124 carriers identified, 106 partners were
tested).
Since prenatal diagnosis was offered only to trait-by-
trait couples, and since we identified only five of these,
the acceptance rate that we observed for prenatal di-
agnosis—four of five, or 80%—is not considered reli-
able. An important determinant is whether pretest ed-
ucation permitted women who would not terminate an
affected pregnancy to choose not to be screened. Such
was generally the case in our study, as assessed by de-
tailed questioning of acceptors and decliners of screening
(even though pretest education was suboptimal in some
respects, as mentioned above). Since we identified no
affected fetuses, we based our rate for termination of
affected fetuses (75%) on questioning at-risk couples,
prior to prenatal diagnosis, about what they would do
if their fetus were found to be affected. In a study of
25,000 women in Scotland, all at-risk couples found to
have an affected fetus terminated the pregnancy (Brock
1996). Thus the low termination rates in couples who
already have an affected child (Wertz et al. 1992) do not
apply to couples whose risk is identified by carrier
screening.
There is limited information on decisions made by
couples whose at-risk status is identified on the basis of
carrier screening—as opposed to couples whose at-risk
status is identified on the basis of having an affected
child—in serial pregnancies. In a small series of couples
whose at-risk status was identified on the basis of having
a CF child, couples who had used prenatal diagnosis in
one pregnancy used it also in subsequent pregnancies
(Evers-Kiebooms et al. 1990). The probabilities used are
shown on a decision tree in figure 1.
Do Costs Exceed Benefits?
A cost-benefit analysis based on the assumptions and
probabilities shown in tables 1 and 2 is shown in table
3. To calculate unit costs, it is conventional to consider
the screening of a population sufficiently large to allow
identification of multiple instances of the disease in ques-
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Table 2
Probability Estimates Used in Base Case and Sensitivity Analysis
Variable
Base
Value
Sensitivity
Range Source
Woman chooses to be screened .57 .20–1.0 Loader (1996), present study
Woman or partner is a carrier .04 (Not varied) U.S. Congress Office of Technology Assessment (1992)
Sensitivity of screening test .85 .75–.90 Cutting (1997), Klinger (1997)
Partner tested if woman is a carrier .85 .5–1.0 Present study
Prenatal diagnosis if couple is at risk .80 .5–1.0 Present study
Prenatal diagnosis reveals affected fetus .25 (Not varied)
Abortion of first affected fetus .75 .5–1.0 Present study
Replacement of affected fetus 1.0 0–1.0 Garber and Fenerty (1991)
Probability of repeat prenatal diagnosis .80 .5–1.0
Probability of abortion of second affected fetusa 1.0 .5–1.0
a After abortion of a previous affected fetus.
tion. Here we postulate that screening is offered to
100,000 pregnant women. In table 3, screening costs are
shown in section A, medical-care costs avoided are
shown in section B, and net screening costs are shown
in section C. In each of the three sections, two cases are
considered: one of them assumes that a couple whose
pregnancy is terminated because of CF does not replace
it by another; the other assumes that a couple whose
pregnancy is terminated because of CF conceives again,
with the same probabilities of having a normal child or
a CF child.
Section A of table 3 shows that the estimated cost of
screening per CF birth voluntarily averted is $1,322,376,
the assumption being that a pregnancy terminated be-
cause of CF is not replaced. If a terminated pregnancy
is replaced, the cost per unwanted CF birth averted is
slightly higher, $1,396,038. The reason for the higher
cost is that the replacement pregnancy entails both in-
creased costs (for additional deliveries, prenatal diag-
noses, and terminations) and the additional possibility
of a CF birth (because we conservatively assumed that
only 80% of such couples would have prenatal diagnosis
for the replacement pregnancy).
To continue the cost-benefit analysis for the popula-
tion of 100,000 women offered screening described in
table 3, we must calculate the cost of medical care for
one individual with CF. This calculation is shown in
table 4. “Direct” cost of care refers to expenses paid by
either the family or its insurer. At $43,083/year for 30
years, this amounts to $1,292,490/patient. “Indirect”
cost of care refers to the estimated cost of care given by
parents. At an average hourly wage of $10, this amounts
to $9,380/year; for the current average CF life span of
30 years, the total is $281,400. The lifetime costs for
direct and indirect care thus total $1,573,890 and equal
the amount saved per case averted. Since the costs of
care are future costs, they must be discounted to allow
for the fact that to have a given amount available at a
future time requires less than that amount today, because
of expected accrual. If a discount rate of 3%/year is
applied, these savings are reduced to $1,028,298/CF case
averted, in today’s dollars.
Table 4 then calculates the cost-effectiveness of CF
carrier screening, by subtracting the discountedmedical-
care costs avoided, $1,028,298, from the cost of averting
the birth of a single unwanted CF child, as shown in
section A of table 3 ($1,322,376). The net cost of screen-
ing per CF birth averted when there is no replacement
is thus $294,078. The higher cost of replacement,
$1,396,038, yields a higher net cost, $367,740. To ex-
press it in relative terms, the savings inmedical-care costs
is estimated to cover 78% of the cost of screening when
there is no replacement and 74% of the cost of screening
when there is replacement.
To return to the calculation at the population level,
section B of table 3 calculates medical-care costs by mul-
tiplying the cost per birth averted (from table 4) by the
number of such terminations (from section A of table
3). Without replacement, the 8.4 CF births averted gen-
erate a total savings of $13,220,676, which is dis-
counted to $8,637,703; on the assumption of replace-
ment, the 7.98 births averted generate a total savings of
$12,559,642, which is discounted to $8,205,818. As
shown in section C of table 3, the net cost to offer screen-
ing to 100,000 pregnant women is either $2,470,252,
without replacement, or $2,934,561, with replacement;
this represents a net cost of $24.70 or $29.35, respec-
tively, per woman offered screening. From this point on
in the analysis, replacement is assumed (for justification,
see the Discussion section).
Does Consideration of the Quality of Life of Child and
Parent Affect the Analysis?
The average utilities by the time–trade-off method-
ology were as follows: 0.70 for affected individuals, 0.90
for their mothers, and 0.95 for their fathers. The value
of .70 for affected individuals means that they reported,
in effect, that they would trade 1.0 year of life with CF
for 0.7 years of life without CF. Mothers reported, in
effect, that they would trade l.0 year of life having a
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Figure 1 Decision tree for analysis of prenatal CF carrier screening. Probabilities shown are derived from the Rochester trial (Loader et
al. 1996).
child with CF for 0.9 year of life having a child without
CF; fathers reported that they would trade 1.0 year of
life having a child with CF for 0.95 year of life having
a child without CF
A cost-utility analysis is presented in table 5. The av-
erage number of years accrued is simply the sum of the
life expectancies of father, mother, and child, at the time
of the CF child’s birth. For the family destined to con-
ceive a CF child, this is a large adjustment, because the
CF child contributes only 30 years, whereas a healthy
child resulting from the replacement strategy contributes
73 years. In terms of QALYs, the difference is larger for
the affected family; for example, the 30 years expected
for the CF child become only 21 QALYs (30 years #
0.7, for quality adjustment). For the whole population,
this difference represents 354 years, as shown in section
B of table 5. The marginal cost utility is the change in
cost per QALY, as a result of the offering of testing. This
value is $8,290, obtained by dividing the medical-costs
difference of the two strategies ($2,934,560) by the dif-
ference in the average number of QALYs, 354, accrued
by families.
Under What Circumstances Would the Cost of
Screening Be Balanced by Averted Medical-Care
Costs?
A sensitivity analysis is presented in tables 6 and 7.
In sensitivity analysis, the most uncertain features and
assumptions are varied, one at a time, over a wide range
of possible values. If the basic conclusions do not change
when a particular feature or assumption is varied, con-
fidence in the conclusion is increased (Weinstein and Sta-
son 1977).
Our sensitivity analysis considered marginal cost-ef-
fectiveness—that is, the cost difference, per QALY, be-
tween the offering of screening and no offering of screen-
ing. For each variable considered, we chose a range of
values intended to reflect conceivable differences among
different types of populations, programs, or technolo-
gies. Variables can be classified as to whether, over the
arbitrarily chosen range of variation, they had a minor,
major, or dominating effect.
As shown in table 6, variables having a minor effect
included the indirect cost of care; the costs of carrier
counseling, of abortion, and of normal delivery; the
probability of either prenatal diagnosis or of abortion
of an affected fetus for a couple having previously
aborted an affected fetus; and the quality-of-life adjust-
ments. Variables having a major effect included the di-
rect cost of care; the cost of offering screening; the sen-
sitivity of the test; and the probabilities of choosing
screening, of a carrier having her partner tested, of a
carrier-carrier couple having prenatal diagnosis, and of
the couple terminating the pregnancy if the fetus has CF.
Finally, certain variables dominated; that is, in the range
considered, for certain values of the variables there was
no marginal cost per QALY, because the decision to test
not only generates QALYs but also saves money rather
than costs money. As shown in table 7, offering testing
saves money if the cost of the laboratory test falls from
$150 to X$100, if the life expectancy of a CF child
increases from 30 years to x54 years, or if the discount
Table 3
Cost-Benefit Analysis: Base Case for 100,000 Screening Offers
A. Cost of Screening Program
No. of Individuals/Couples/Fetuses or Type of Cost Unit Cost or Rate/Probability Total
Without replacement:
Women offered screening  100,000 # Cost of offering test  $20  $2,000,000
Women accepting  100,000 # 57% Acceptance rate  57,000 Women
Women tested  57,000 # Cost of testing  $150  $8,550,000
Women tested  57,000 # Carrier rate  .04 # test
sensitivity  .85
 1,938 Carriers identified
Carriers counseled  1,938 # Cost of counseling  $150  $290,700
Carriers counseled  1,938 # 85% of partners tested  1647.3 Partners tested
Partners tested  1647.3 # Cost of testing  $150  $247,095
Partners tested  1647.3 # Carrier rate  .04 # test
sensitivity  .85
 56 Couples at risk
Couples at risk  56 # Cost of repeat counseling  $60  $3,360
Couples at risk  56 # Probability of accepting PD  .80  44.8 Couples having PD
Couples having PD  44.8 # Cost of PD  $900  $40,320
Couples having PD  44.8 # Probability of affected fetus  .25  11.2 Affected fetuses
Affected fetuses  11.2 # Probability of termination  .75  8.4 Terminations
Terminated pregnancies  8.4 # (Cost of termination  averted cost
of delivery)  ($2,800)
 $23,520
Total cost/100,000 women offered screening  $11,107,955
Cost of screening per CF birth voluntarily averted (Total cost of screening 
$11,107,955)  (no. of terminations
 8.4)
 $1,322,376
With replacement:
Terminations  8.4 # Probability of replacement of
aborted fetus  1
 8.4 Pregnancies
Pregnancies  8.4 # Probability of having PD  .80  6.72 Couples having PD
Couples having PD  6.72 # Cost of PD  $900  $6,048
Couples having PD  6.72 # Probability of affected fetus  .25  1.68 Affected fetuses
Affected fetuses  1.68 # Probability of termination  1  1.68 Terminations
Terminations  1.68 # Cost of termination  $900  $1,512
Replacement fetuses carried to term  6.72 # Cost of delivery  $3,700  $24,864
Extra cost of replacement  $32,424
Total cost/100,000 women offered testing $11,107,955  $32,424  $11,140,379
Replacement fetuses  8.4 # (1  Probability of having PD)  .2  1.68 Couples not having PD
Couples not having PD  1.68 #Probability of affected fetus  .25  .42 CF births
CF births averted from first pregnancy  8.4  No. of CF births from second preg-
nancy  .42
 7.98 CF births averted
Cost of screening per CF birth voluntarily averted (Total cost of screening 
$11,140,379)  (no. of CF births
averted  7.98)
 $1,396,038
B. Medical-Care Costs Avoided
Type of Cost Total
Without replacement:
Total cost (direct  indirect)  $1,573,890a# 8.4 CF births averted  $13,220,676
Total cost discounted at 3% $8,637,703
With replacement:
Total cost (direct  indirect)  $1,573,890a# 7.98 CF births averted  $12,559,642
Total cost discounted at 3% $8,205,818
C. Screening Costs
Without Replacement With Replacement
Total screening costs $11,107,955 $11,140,379
Care costs avoided $8,637,703 $8,205,818
Net screening costs $2,470,252 $2,934,561
NOTE.—PD  prenatal diagnosis.
a From table 4.
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Table 4
Summary of Analysis of Cost per CF Birth Averted
A. Medical-Care Costs Avoided per CF Birth Averted
Type of Cost Total
Direct: $43,083/year # 30 years  $1,292,490
Indirect: $10/h # 938 h/year # 30 years  $281,400
Total $1,573,890
Total discounted at 3% $1,028,298
B. Screening Costs per CF Birth Averted
Without Replacement With Replacement
Total screening costs $1,322,376 $1,396,038
Care costs avoided discounted at 3% $1,028,298 $1,028,298
Net screening costs $294,078 $367,740
rate falls from 3% to X0.9%; in contrast, offering test-
ing both costs money and decreases QALYs if the prob-
ability that a pregnancy follows abortion of an affected
fetus falls to !.25.
How Much Is CF Screening Worth to Patients?
Although our study offered free screening, we asked,
when women accepted, howmuch they would be willing
to pay for it had there been a charge. The results are
shown in table 8. The answer chosen by the vast majority
was the cheapest of the alternative answers provided,
$0–25, a price far below the current commercial charge.
Discussion
The adoption of new health-care services is con-
strained by limited health-care resources. As a result,
economic analysis is appropriate before new services are
adopted. An economic analysis attempts to identify and
quantitate all relevant variables. These include all health
benefits and burdens and all current and future costs
and savings. This study considered the value of prenatal
CF carrier screening by using three different analytic
approaches. One approach evaluated the net cost of
screening, or cost-benefit; a second approach analyzed
cost-utility, which takes into account quality of life; a
third approach examined patient willingness to pay for
the service.
The Cost-Benefit Approach
The results of our analysis show that, given our base-
line assumptions, the costs of screening are not offset by
the expense avoided. Even though the costs of caring for
an affected child are substantial, identification of an af-
fected fetus is a relatively rare event. In Rochester, 4,879
tests resulted in identification of only five at-risk couples.
Nevertheless, the costs of screening would be balanced
by the medical-care costs averted if there should be a
change, in a favorable direction, in any one of several
variables (table 7). Some of the changes listed are un-
likely to occur. For example, it is unlikely that a discount
rate of !0.9% would ever be justified. A mean life ex-
pectancy of x54 years for an individual with CF would
require unanticipated improvements in management.
However, a decrease in test cost to !$100 is a distinct
possibility. The recent National Institutes of Health rec-
ommendation for routine prenatal CF carrier screening
(“Genetic Testing for Cystic Fibrosis” statement of the
National Institutes of Health 1997) may increase the
utilization of carrier screening and ultimately increase
competition among laboratories, reducing the cost of
testing. Furthermore, hybridization to high-density oli-
gonucleotide arrays can provide efficient screening for
large numbers of mutations (Chee et al. 1996) and ul-
timately may reduce costs.
Our economic analysis did not take into consideration
the anxiety associated with testing, except as it was re-
flected in choices that individuals made. We have since
conducted a 1-year follow-up of women identified as
being carriers and have found that most women iden-
tified as being carriers were, in retrospect, content with
the screening decision that they had made (Levenkron
et al. 1997). On the benefit side, we did not consider
that the individual identified as a carrier (a) is informed
for any subsequent pregnancy and (b) may alert relatives
to their increased risk. Thus there are potential benefits
beyond the pregnancy in which testing occurs.
The Cost-Utility Approach
The second model used cost-utility analysis. Cost-util-
ity analysis may be preferable to cost-effectiveness anal-
ysis in cases in which the quality of life is the most
important outcome characteristic (Drummond and Da-
vies 1991). In contrast to the cost-benefit model, which
creates a ratio of treatment costs to costs averted, the
cost-utility model considers the cost necessary to achieve
1168 Am. J. Hum. Genet. 63:1160–1174, 1998
Table 5
Cost-Utility Analysis for Screening Assuming Replacement
A. Base Case for Screening Offered to 100,000 Women
Category Total
I. Test not offered:
100,000 Pregnant women # carrier rate  .04  4,000 Carriers
4,000 Carriers # carrier rate for spouse  .04  160 Couples at risk
160 Couples at risk # probability of affected fetus  .25  40 CF children
Medical cost:
Per CF child, discounted at 3% (from table 4) $1,028,298
For 40 CF children  40 # $1,028,298  $41,131,920
Life years expected:
CF present:
Individual with CF: 30 years # .7 quality adjustment  21.0 years
Mother: 78.8  25 (current age)  53.8 years # .9 quality-of-life adjustment  48.4 years
Father: 71.9  25 (current age)  46.9 years # .95 quality adjustment  44.6 years
Total  114.0 years
CF absent:
Individual without CF  73.0 years
Mother  53.8 years
Father  46.9 years
Total 173.7 years
Per 100,000 families with pregnancies:
40 CF families # 114 years  4,560 years
99,960 Non-CF families # 173.7 years  17,363,052 years
Total  17,367,612 years
II. Test offered:
No. of CF children: 40  7.98 CF births averted (from table 3)  32.02
Medical-care costs (discounted at 3%) for 32.02 CF children # $1,028,298  $32,926,101
Life years expected, for families with:
CF child: 32.02 # 114 years/family  3,650.3 years
No child: 1.68 # (53.8  46.9) years/family  169.2 years
Normal child: 99,966.3 # 173.7 years/family  17,364,146.3 years
Total  17,367,965.8 years
Cost of offering screening (from table 3) $11,140,379
Total costs of screening (discounted medical costs  screening costs) $44,066,480
B. Marginal Cost-Utility
Without Screening With Screening Difference
Medical-care costs $41,131,920 (care of 40 CF children) $32,926,101 (care of 32.02 children)
Screening costs 0 $11,140,379
Total costs $41,131,920 $44,066,480 $2,934,560
QALYs 17,367,612 17,367,966 354
Marginal cost per
QALY
$290
the equivalent of 1 year of healthy life. The method uses
a metric, QALY, that adjusts life expectancy for quality
of life. In traditional life-expectancy analysis, each in-
dividual in a birth cohort is coded as 1.0 for each re-
maining year of life and is coded as 0 if dead. Quality-
adjusted life-expectancy analysis assigns wellness scores
of 0.0–1.0 on the basis of health-related quality of life.
The estimates of the cost necessary to produce aQALY
depend on assumptions about replacement pregnancy. If
we assume that a family loses life years by terminating
a pregnancy, then the program causes a loss of life years
and would not be beneficial in cost-utility terms, because
it would result in a net loss of family QALYs. However,
if the pregnancy is replaced, then the program would
produce ∼354 QALYs from 100,000 screening offers.
The cost to produce each additional QALY thus is es-
timated to be $8,290. Table 9 shows the marginal cost
per QALY of the CF screening program, compared with
those of many other widely advocated interventions. As
the table shows, the cost-utility ratio for prenatal CF
carrier screening is comparable to that for newborn
screening for phenylketonuria and is more advantageous
than the ratios for many widely advocated preventive
interventions. Whether a preventive measure involving
prenatal diagnosis and selective termination can be fairly
compared with prevention measures that do not involve
these choices is discussed further in the Pregnancy-Re-
lated Issues subsection (below).
In the present study, utilities were assessed by means
of a time–trade-off method with individuals with CF and
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Table 6
Marginal Cost-Utility for Screening Assuming Replacement: Sensitivity Analysis
VARIABLE (RANGE)
COST PER QALY FOR
($)
Minimum Value
of Variable
Maximum Value
of Variable
Direct-care costs per CF child per year ($10,000–$60,000) $22,823 $729
Indirect-care costs per CF child per year (700–1,000 h) $9,256 $7,930
Cost of offering screening ($20–$100) $8,290 $30,742
Cost of laboratory test ($20–$200) (Dominated [offer-
ing of test is pre-
ferred option])
$16,466
Cost of carrier counseling ($100–$200) $7,931 $8,477
Cost of termination of pregnancy ($400–$1,200) $8,190 $8,213
Cost of normal delivery ($1,800–$5,000) $8,213 $8,198
Sensitivity of test (.75–.90) $16,861 $4,909
Probability that screening is chosen (.2–1) $18,628 $5,782
Probability that partner is tested if woman is a carrier (.5–1) $29,721 $3,693
Probability of prenatal diagnosis if both partners are carriers (.5–1) $26,953 $1,955
Probability of abortion of affected fetus (.5–1) $23,855 $364
Probability of pregnancy after abortion of an affected fetus (0–1) (Dominated [no offer-
ing of test is pre-
ferred option])
$8,290
Probability of prenatal diagnosis after abortion of an affected fetus (.5–1) $9,801 $7,097
Probability of abortion of an affected fetus after abortion of a previous affected fetus (.5–1) $10,326 $8,290
Quality-of-life adjustment for mother of CF child (.2–.95) $4,437 $8,734
Quality-of-life adjustment for CF child (.1–1.0) $5,836 $10,293
Life expectancy of CF child (30–73 years) $8,290 (Dominated [offer-
ing of test is pre-
ferred option])
Discount rate (0%–7%) (Dominated [offer-
ing of test is pre-
ferred option])
$16,710
their parents. It is acknowledged that the time–trade-off
method asks subjects to make judgments in hypothetical
situations that many patients find difficult to make. A
possible bias is for such individuals to minimize the toll
that CF exacts. However, if the burden thus estimated
has been underestimated, the benefit of screening also
has been underestimated. A few might even argue that
having a child with CF improves rather than impairs
health-related quality of life. Some parents report a
higher degree of satisfaction and bonding with children
who confront serious health problems (Botkin 1990;
Hilgers and Horan 1972). Another concernwith quality-
of-life adjustment is that we used a constant value for
the adjustment over the whole course of the disease,
rather than illness-stage–specific values. Thus the ad-
justment must be considered to be very crude.
The Willingness-to-Pay Approach
For most consumer services and products, market
forces influence price. Health-care services are different.
Medical care is unusual because there is often no clear
connection between price and consumer willingness to
pay.
The willingness-to-pay approach to valuation of
health services is considered to have the advantage of
enabling the respondent to express the benefits of health
care in terms of their effect on quality of life, as well as
on quantity of life. This approach was used by Mied-
zybrodzka et al. (1995) and Donaldson et al. (1997) in
comparisons of stepwise versus couple-carrier screening
for CF.
In the present study, women were asked what they
would be willing to pay for the genetic-screening test if
it were not covered by insurance. The modal response
(77%) was X$25. Nearly 94% of the respondents
would pay X$50 for the test. It was similar for the 427
women who declined screening. On the one hand, these
findings may suggest that women may not be unusually
concerned about obtaining screening. On the other
hand, in asking subjects howmuch they would bewilling
to pay for CF screening, we found that people had great
difficulty in providing an estimate. One reason is that
many people do not receive bills for laboratory tests and
therefore have no frame of reference for answering such
a question.
Economic Feasibility of Widespread CF Carrier
Screening
At the time of the writing of this article, it was unclear
how widely the National Institutes of Health recom-
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Table 7
Threshold Values for Cost-Utility for Screening Assuming Replacement
Variable
Base-Case
Value
Option That Becomes Dominant When Variable Is
Changed To
Cost of laboratory test $150 Offer screening !$100.35
Life expectancy of CF child 30 years Offer screening 153.8 years
Discount rate 3% Offer screening !.9%
Probability of replacement of aborted fetus 1.0 Do not offer screening !.24
Table 8
Amount That Women Would Be Willing to
Pay for Screening
Cost Range ($) No. of Women Percentage
0–25 1,678 77.2
26–50 371 17.1
51–75 68 3.1
76–100 30 1.4
101–125 8 .4
126–175 1 .0
176–250 4 .2
1250 14 .6
mendation to routinely offer prenatal CF carrier screen-
ing will be adopted. If it is widely adopted, there will
be pressure on third parties to pay for it even though
the costs are immediate whereas the economic benefits
are delayed. However, if such screening does not become
routine, our studies suggest that it is unlikely that many
providers will offer it or that many patients without a
family history of CF will request it. Patients are unlikely
to pay for screening themselves because of a generally
modest interest in being tested, the test’s current signif-
icant cost, and their being unaccustomed to paying out-
of-pocket for prenatal care.
Methodological Issues
1. Quantifiability.—Botkin (1990) lists some intangible
benefits and harms that may be associated with prenatal
screening—for example, anxiety generated by the testing
procedure and by waiting for the result, reassurance as-
sociated with receiving a normal result, and anguish as-
sociated with the abortion of an abnormal fetus. He
concludes that cost-benefit approaches are too crude for
dealing with the value-laden issues associated with pre-
natal screening and that utilitarian considerations will
not produce a clear and morally acceptable standard by
which resources can be distributed, without our placing
explicit values on complex intangibles, including the so-
cial worth of a disabled child. The quality-of-life ad-
justment may be too crude to identify those subtle var-
iations in psychological state.
2. Pregnancy-related issues.—Morris (1994) has crit-
icized analyses of prenatal screening programs by cost-
benefit methods on the grounds that they fail to quantify
psychological effects, in three regards. First, in such pro-
grams, prevention necessarily involves pregnancy ter-
mination, and abortion is not an option for many
women. Second, he states that those who do counte-
nance abortion do not agree on what fetal conditions
justify it and that abortion for a given condition may
stigmatize persons with that condition. Third, he fears
that a prevention-oriented screening program may re-
place the individual’s appreciation for the value inherent
in raising a disabled child.
We acknowledge that pregnancy termination is not
regarded as an option by all patients, even when the
fetus is shown to have the genotype for a serious genetic
disease—and that this is particularly so for a disease that
confers neither mental retardation nor malformations.
In such a context, it is especially important that a pro-
jection of outcomes utilizes data on choices that couples
are observed to make in this situation, as we have tried
to do.
The results of our analysis are very sensitive to as-
sumptions about replacement. First of all, we acknowl-
edge that our analysis, insofar as we have assumed re-
placement, is making an analogy between a replacement
pregnancy and effective treatment of the affected fetus,
an analogy that many would not accept.
Typically, cost-utility analysis begins at birth. Thus,
therapeutic abortion is not associated with either gains
or losses of life years. Once a child is born, years of life
accrue. A child with CF would have fewer QALYs than
would a well child. Thus, in the analyses shown in tables
5–9, we have assume that an aborted pregnancy will be
replaced by another pregnancy. Since there are few pub-
lished data on serial pregnancies in couples whose risk
of having a CF child is discovered by carrier screening,
we have adopted the assumption made by Garber and
Fenerty (1991)—that, since the desire to give birth to an
unaffected child is the primary reason for testing, indi-
viduals who choose testing and who terminate a preg-
nancy for CF would be expected to pursue a replacement
strategy.
An alternative scheme begins cost-utility analysis at
conception or at the time when a fetus becomes physi-
ologically viable. Thus, an aborted fetus could accrue
the number of QALYs equal to the total life expectancy
(Ganiats 1996). Similarly, the estimate of the family life-
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Table 9
Marginal Cost per QALY for Selected Preventive Measures
Intervention
Marginal Cost
per QALYa
($) Reference
Pneumococcal vaccine for elderly 1,765 U.S. Congress Office of Technology Assessment (1979)
Postpartum anti–rhesus D injection 2,109 Torrance and Zipursky (1984)
Smoking-cessation counseling 6,463 Schulman and Linas (1997)
T4 thyroid screening 7,595 Epstein et al. (1981)
Prenatal CF carrier screeningb 8,290 Present study
Newborn phenylketonuria screening 8,498 Bush et al. (1973)
Postmenopausal estrogen therapy 32,057 Weinstein (1980)
School tuberculin-testing program 43,250 Bush et al. (1972)
Screening mammography 167,850 Eddy (1989)
a Costs are adjusted to current dollar values.
b This preventive measure, unlike the others, involves prenatal diagnosis and selective pregnancy termination.
years would be those of the parents, less those thatwould
have accrued to the aborted fetus. We believe that such
an accounting system would be unusual and not clearly
justified. However, we have included this case in the
analysis, within the category termed “without replace-
ment.” In view of the small number of terminated preg-
nancies, the replacement variable had only a small effect
on average life-years per family, but it did swing the
conclusion either away from screening, if there were no
replacement, or toward screening, if replacement were
assumed.
With regard to the accounting for the costs of a ter-
minated pregnancy, there is some inconsistency in the
literature . Ganiats (1996) reviewed the 41 English-lan-
guage papers published during 1993–96, using “amni-
ocentesis,” “cost,” and “quality of life” as the search
terms. The dominant methodology was to value impact
on patients, without attempting to consider life lost by
the aborted fetus. The difficulty is that the analyses often
account for medical savings that are prevented through
pregnancy termination, without considering any poten-
tial benefits that would accrue if the pregnancy were
completed.
3. Unaffected children.—Another important assump-
tion was the exclusion of medical-care costs incurred for
unaffected children. Many analysts believe that these
costs should be included. Children accrue medical-care
costs, whether or not they are affected by CF. The issue
is the differential health-care cost; in other words, what
are the incremental expenditures required for a child
with an illness such as CF? Although this is an interesting
philosophical issue, using incremental costs in this anal-
ysis would not have altered the conclusions.
Discounting.—Although there is no question that fu-
ture costs must be discounted, there is currently a dif-
ference of opinion about which discount rate is most
appropriate. Although a 5% rate traditionally has been
used, a rate of 3% recently has been recommended
(Weinstein et al. 1996). A broad range of discount rates
(0%–7%) is included in the sensitivity analysis.
Some also would discount expected years of life, on
the grounds that persons may value future benefits less
they value than current benefits. However, we have not
chosen to do this, since such discounting is based not
on any economic reality (Ganiats 1996) but, rather, per-
haps, on a psychological bias that may not merit being
promoted.
Limitations
1. Comprehensiveness.—In our model system, even
with economic barriers removed, screening proved to be
very incomplete. The probability that a fetus with a CF
genotype who was carried by a woman in our region
during the period of study would have been identified
in our trial can be calculated as follows: (proportion of
providers offering screening  30%) # (proportion of
pregnant women accepting screening  57%) # (pro-
portion of carriers identified  85%) # (proportion of
carrier women having their partners tested  85%) #
(proportion of at-risk couples who accept prenatal di-
agnosis  80%)  9.9%. In other words, despite the
offer of free testing and counseling, which was made
known to all prenatal-care providers, the chance that an
affected fetus in this region during this time period
would have been identified was !1/10. The greatest bar-
rier to universal screening was that fewer than one-third
of the providers offered screening. The second greatest
barrier was patient reluctance to accept screening. How-
ever, insofar as our 57% patient-acceptance rate was
based on an understanding of the significance of what
was being offered, one cannot wish that it had been
higher; the foremost purpose of prenatal screening is not
to reduce the incidence of genetic disease but to fulfill a
couple’s reproductive goals.
2. Unidentified burdens.—We are aware that burdens
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to be encountered elsewhere may have gone undetected
in Rochester. Rochester is a community with low un-
employment and an extensive health-care system.
Although we offered participation to all prenatal-care
providers in the county, only a minority submitted sam-
ples, and this minority may have accorded a higher pri-
ority to such screening and therefore may have devoted
more effort to it than would providers who offer screen-
ing only because of external pressures. Providers who
feel coerced may spend even less time educating patients,
with consequently less favorable outcomes.
Comparison with Other Analyses of Cost-Effectiveness
of CF Carrier Screening
Economic analyses of population carrier screening for
CF also have been reported by others. Garber and Fe-
nerty (1991) found a small surplus of economic benefits
over costs if any fetus lost because of a prenatal diagnosis
of CF was followed by the birth of a healthy child, but
not otherwise. Mennie et al. (1992) predicted an excess
of economic benefits over costs but assumed a very low
test cost and, apparently, that 100% of partners of car-
riers would be tested.Wilfond and Fost (1992) estimated
a cost of $2,400,000/CF child averted; however, they
assumed that everyone screened would receive profes-
sional genetic counseling, whether identified as being a
carrier or not, and that only a small proportion of trait-
by-trait couples would be willing to undergo prenatal
diagnosis. However, professional genetic counseling for
those testing negative is unlikely to be prescribed, and
our study found that, even in a primary-care setting,
women who were not interested in prenatal diagnosis
generally declined the offer of screening.
The detailed study by the U.S. Congress Office of
Technology Assessment (1992) concluded that an excess
of costs over benefits was likely unless either the test cost
!$100 or all at-risk couples had prenatal diagnosis and
terminated the pregnancy if the fetus were identified as
being affected. Their analysis assumed that screening
would be preconceptional; this type of screening is less
efficient, because some of the identified carriers never
become pregnant. In fact, our study found that obste-
trician-gynecologists generally did not offer screening to
nonpregnant women, because it was less convenient or
appeared to be less urgent.
Asch et al. (1993) estimated the cost per CF birth
averted as being $449,823 for two-step screening but
$821,692 for couple screening. “Couple screening” is
the screening of both members of a couple at the same
time and informing them about carrier status only if both
of them are carriers. Brock (1996) prefers couple screen-
ing over the two-step method employed here, because it
avoids the anxious period, in two-step screening, be-
tween informing a woman that she is a carrier and re-
ceiving a negative result for her partner. However, the
couple method is even more expensive per CF birth
averted, because it requires the testing of every partner,
not just partners of carriers. More recently, Asch et al.
(1996) have compared 15 strategies for prenatal CF car-
rier screening and have discussed thoughtfully the special
issues that complicate the economic analysis of genetic
screening for reproductive purposes.
Lieu et al. (1994) reported a cost of $1,411,000/un-
wanted CF birth averted and that the principal deter-
minants were test cost, test sensitivity, and the propor-
tion of at-risk couples choosing prenatal diagnosis.
Analyses also have been conducted in the United King-
dom (Watson et al. 1991; Cuckle et al. 1995), Denmark
(Schwartz et al. 1993), and Israel (Ginsberg et al. 1994).
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